CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 3 (Patent Applications = 4)

Average Co-Inventor Count = 3.7

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

9 out of 112

Sorrento Therapeutics, Inc.

Years Active: 2014-2024

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084503 - Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) and methods of use thereof for treatment (2024-09-10),

2. 11111304 - Fully human antibodies that bind to vascular endothelial growth factor receptor 2 (VEGFR2) (2021-09-07),

3. 10696746 - Antigen binding proteins that bind CCR2 (2020-06-30),

4. 10519245 - Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer (2019-12-31),

5. 10472413 - Anti-infective binding proteins that bind AIP2 (2019-11-12),

6. 9951138 - Antigen binding proteins that bind CCR2 (2018-04-24),

7. 9631009 - Anti-infective binding proteins that bind AIP2 (2017-04-25),

8. 9315579 - Antigen binding proteins that bind CCR2 (2016-04-19),

9. 9029510 - Fully human antibodies that bind to VEGFR2 and methods of use thereof (2015-05-12),

10. 8859740 - Anti-infective binding proteins that bind AIP2 (2014-10-14),

Title: Guodi Lu: Innovator in Cancer Treatment Through Fully Human Antibodies

Introduction

Guodi Lu, located in San Diego, CA, is a prominent inventor recognized for his significant contributions to the field of biomedicine. With a remarkable portfolio of 10 patents, his work primarily focuses on developing fully human antibodies that target vascular endothelial growth factor receptor 2 (VEGFR2). His innovations aim to provide advanced therapeutic options for cancer treatment.

Latest Patents

Among Guodi Lu's latest patents are compositions and methods related to anti-VEGFR2 antibodies. His research has disclosed fully human antibodies that effectively bind to VEGFR2, along with various VEGFR2-binding fragments and derivatives. This innovative work includes antibody fragments and polypeptides, detailing methods for using these antibodies in treating or diagnosing patients with different types of cancers. These patents underline the potential of his discoveries to improve medical outcomes for cancer patients.

Career Highlights

Guodi Lu has built a successful career in biopharmaceuticals, contributing to significant advances in cancer therapies. He has held key positions at reputable companies such as Sorrento Therapeutics, Inc. and Vivasor, Inc., where his expertise has been instrumental in expanding the understanding and application of fully human antibodies in clinical settings.

Collaborations

Throughout his career, Guodi Lu has collaborated with notable peers, including Heyue Zhou and John Dixon Gray. These partnerships have fostered a productive exchange of ideas and expertise, furthering the development of innovative cancer treatments based on his research.

Conclusion

Guodi Lu stands out as an influential figure in the realm of medical innovation. His diligent work on fully human antibodies targeting VEGFR2 showcases his commitment to enhancing cancer therapeutic options. As the landscape of biomedicine evolves, inventors like Guodi Lu will undoubtedly continue to pave the way for groundbreaking advancements in cancer treatment.

This text is generated by artificial intelligence and may not be accurate.